MRSN - メルサナ・セラピュ―ティクス (Mersana Therapeutics Inc.) メルサナ・セラピュ―ティクス

 MRSNのチャート


 MRSNの企業情報

symbol MRSN
会社名 Mersana Therapeutics Inc (メルサナ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 メルサナ・セラピューティクス(Mersana Therapeutics Inc.)はバイオテクノロジー企業である。同社は抗体医薬複合体(ADC)パイプラインの発見と開発に従事する。同社はFleximerイムノコンジュゲート技術を活用した標的腫瘍治療薬パイプラインの推進に重点を置く。Fleximerプラットフォームにより、同社は特定特性を持つADCを設計し、癌の攻撃機会を管理できる。製品候補には、XMT-1522とXMT-1536が含まれる。ADC療法は抗癌剤との薬物コンジュゲートを操作して癌患者を治療する。DolaflexinはFleximerポリマーをリンカー化学物質とペアにしてADC療法を作成するFleximer抗体薬物接合プラットフォームである。   メルサナ・セラピュ―ティクスはアメリカのバイオ医薬品企業。臨床段階で、抗体医薬複合体(ADC)に焦点を当て、がん患者向けの治療法を開発する。免疫複合療法を開発し、比較的少量のHER2タンパク質を発現するXMT-1522を提供する。同社の「Dolaflexin」プラットフォ―ムを活用したパ―トナ―シップも展開する。本社はマサチュ―セッツ州ケンブリッジ。   Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in oncology indications. Its product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC) and XMT-1536, which focuses on ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
本社所在地 840 Memorial Drive Cambridge MA 02139 USA
代表者氏名 David M. Mott デビッド・モット
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-498-0020
設立年月日 37288
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 78人
url www.mersana.com
nasdaq_url https://www.nasdaq.com/symbol/mrsn
adr_tso
EBITDA EBITDA(百万ドル) -46.81100
終値(lastsale) 8.99
時価総額(marketcap) 208149227.82
時価総額 時価総額(百万ドル) 185.69040
売上高 売上高(百万ドル) 16.78300
企業価値(EV) 企業価値(EV)(百万ドル) 89.18140
当期純利益 当期純利益(百万ドル) -46.45600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Mersana Therapeutics Inc revenues decreased 10% to $7.3M. Net loss increased 46% to $24.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase from $10.6M to $24.9M (expense) General and administrative increase from $2.2M to $7.8M (expense).

 MRSNのテクニカル分析


 MRSNのニュース

   Why Mersana Therapeutics (MRSN) Could Be Positioned for a Surge  2020/06/04 12:30:00 Zacks Investment Research
Mersana Therapeutics (MRSN) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
   Why Mersana Therapeutics (MRSN) Stock Might be a Great Pick?  2020/05/28 12:55:00 Zacks Investment Research
Mersana Therapeutics (MRSN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Mersana Stock Spikes on Interim Data on Cancer Candidate  2020/05/28 08:42:00 Zacks Investment Research
Mersana's (MRSN) antibody-drug conjugate candidate, XMT-1536, achieves encouraging response rate in interim analysis of a phase I study in ovarian cancer patients.
   Stock Alert: Mersana (MRSN) Working To Make 2020 A Transformational Year?  2020/02/18 00:34:00 RTT News
Mersana Therapeutics Inc. (MRSN), which believes that 2020 has the potential to be a transformational year for it, has gained 36 percent so far this year, based on Feb.
   Mersana Therapeutics (NASDAQ:MRSN) Sees Large Volume Increase  2019/11/14 05:23:52 Modern Readers
Shares of Mersana Therapeutics Inc (NASDAQ:MRSN) saw unusually-strong trading volume on Wednesday . Approximately 950,700 shares traded hands during trading, an increase of 292% from the previous session’s volume of 242,340 shares.The stock last traded at $2.78 and had previously closed at $2.30. Several analysts recently issued reports on MRSN shares. HC Wainwright reaffirmed a […]
   Why Mersana Therapeutics (MRSN) Could Be Positioned for a Surge  2020/06/04 12:30:00 Zacks Investment Research
Mersana Therapeutics (MRSN) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
   Why Mersana Therapeutics (MRSN) Stock Might be a Great Pick?  2020/05/28 12:55:00 Zacks Investment Research
Mersana Therapeutics (MRSN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Mersana Stock Spikes on Interim Data on Cancer Candidate  2020/05/28 08:42:00 Zacks Investment Research
Mersana's (MRSN) antibody-drug conjugate candidate, XMT-1536, achieves encouraging response rate in interim analysis of a phase I study in ovarian cancer patients.
   Stock Alert: Mersana (MRSN) Working To Make 2020 A Transformational Year?  2020/02/18 00:34:00 RTT News
Mersana Therapeutics Inc. (MRSN), which believes that 2020 has the potential to be a transformational year for it, has gained 36 percent so far this year, based on Feb.
   Mersana Therapeutics (NASDAQ:MRSN) Sees Large Volume Increase  2019/11/14 05:23:52 Modern Readers
Shares of Mersana Therapeutics Inc (NASDAQ:MRSN) saw unusually-strong trading volume on Wednesday . Approximately 950,700 shares traded hands during trading, an increase of 292% from the previous session’s volume of 242,340 shares.The stock last traded at $2.78 and had previously closed at $2.30. Several analysts recently issued reports on MRSN shares. HC Wainwright reaffirmed a […]
   Stock Alert: Mersana (MRSN) Working To Make 2020 A Transformational Year?  2020/02/18 00:34:00 RTT News
Mersana Therapeutics Inc. (MRSN), which believes that 2020 has the potential to be a transformational year for it, has gained 36 percent so far this year, based on Feb.
   Mersana Therapeutics (NASDAQ:MRSN) Sees Large Volume Increase  2019/11/14 05:23:52 Modern Readers
Shares of Mersana Therapeutics Inc (NASDAQ:MRSN) saw unusually-strong trading volume on Wednesday . Approximately 950,700 shares traded hands during trading, an increase of 292% from the previous session’s volume of 242,340 shares.The stock last traded at $2.78 and had previously closed at $2.30. Several analysts recently issued reports on MRSN shares. HC Wainwright reaffirmed a […]
   $500,000.00 in Sales Expected for Mersana Therapeutics Inc (NASDAQ:MRSN) This Quarter  2019/11/12 04:15:58 Modern Readers
Wall Street brokerages expect Mersana Therapeutics Inc (NASDAQ:MRSN) to announce $500,000.00 in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Mersana Therapeutics’ earnings. The lowest sales estimate is $250,000.00 and the highest is $1.00 million. Mersana Therapeutics posted sales of $1.19 million in the same quarter last year, which […]
   The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment  2019/11/05 11:53:31 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 4) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally following positive Adcom verdict for Twirla) Amgen, Inc. (NASDAQ: AMGN ) Beigene Ltd (NASDAQ: BGNE ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Frequency Therapeutics Inc (NASDAQ: FREQ ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Karyopharm Therapeutics Inc (NASDAQ: KPTI )(reacted to its third-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) (IPOed Oct. 31) Phathom Pharmaceuticals Inc (NASDAQ: PHAT ) Recro Pharma Inc (NASDAQ: REPH ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 4) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Midatech Pharma PLC-ADR (NASDAQ: MTP ) Rockwell Medical Inc (NASDAQ: RMTI ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Stocks In Focus Seattle Genetics Claims Rights To Disputed Antibody-Drug Conjugate Intellectual Property Following the filing of a declaratory judgment action by DAIICHI SANKYO/S ADR (OTC: DSNKY ), Seattle Genetics, Inc. (NASDAQ: SGEN ) said the antibody-drug conjugate tech used in Daiichi Sankyo's metastatic cancer drug candidate DS-820 , among others, rightfully belongs to it. "The linker and other ADC technology used in these drug candidates are improvements to Seattle Genetics' pioneering ADC technology, the ownership of which are automatically assigned to Seattle Genetics under the terms of the agreement," the company said.
   The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave  2019/09/27 11:56:12 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 26.) AstraZeneca plc (NYSE: AZN ) GlaxoSmithKline plc (NYSE: GSK ) Sanofi SA (NASDAQ: SNY ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Aduro BioTech Inc (NASDAQ: ADRO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) AnaptysBio Inc (NASDAQ: ANAB ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) AzurRx BioPharma Inc (NASDAQ: AZRX ) Bellerophon Therapeutics Inc (NASDAQ: BLPH ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (announced submission of clinical trial application to U.K. regulators for its investigational therapy for phenylketonuria) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) CytomX Therapeutics Inc (NASDAQ: CTMX ) strong>DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) ( announced mid-stage results of NASH treatment candidate) Enochian Biosciences Inc (NASDAQ: ENOB ) Erytech Pharma SA (NASDAQ: ERYP ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Gritstone Oncology Inc (NASDAQ: GRTS ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) IGM Biosciences Inc (NASDAQ: IGMS ) (initial public offering on Sept.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 メルサナ・セラピュ―ティクス MRSN Mersana Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)